PCMA Statement on Comparative Effectiveness

Wednesday, March 19, 2008 General News
Email Print This Page Comment
Font : A-A+

WASHINGTON, March 18 The Pharmaceutical Care Management Association (PCMA) issued the following statement today regarding various comparative effectiveness proposals that are being debated in Congress:



"PCMA believes comparing the clinical effectiveness of competing drug therapies is an important tool in promoting value-based purchasing. Pharmacy benefit managers have led the way with Pharmacy & Therapeutics (P&T) committees and a wide range of proven utilization tools -- including multi-tier formularies and step therapy -- to ensure patients have access to cost-effective and clinically proven prescription drugs.



"PCMA urges policy makers to explore collaborative opportunities in the public and private arenas where comparative effectiveness can successfully be implemented."



PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D.



SOURCE Pharmaceutical Care Management Association


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook